Companies in the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval. But with the risk of failure, which could spell disaster for a stock, comes great reward as well. Some companies can see a massive upside just from winning a single midstage trial or even achieving as much as a Fast Track designation from the U.S. Food and Drug Administration (FDA).
Here, 24/7 Wall St. has included a calendar of a few of companies to watch for in the coming week and for the month of July.
Ascendis Pharma A/S (NASDAQ: ASND) is expected to present full Phase 1 data from its TransCon-PTH hypoparathyroidism treatment later this month. Shares of Ascendis closed Friday at $66.52, with a consensus analyst target price of $84.66 and a 52-week trading range of $25.50 to $76.29.
Epizyme Inc. (NASDAQ: EPZM) is expected to issue an update on its partial clinical hold of tazemetostat following reports of a child with advanced poorly differentiated chordoma, a rare bone cancer, developing a secondary T-cell lymphoma. Trial enrollment outside the United States has not been affected. Shares of Epizyme closed Friday at $13.55, in a 52-week range of $11.15 to $21.40 and with a consensus analyst target of $25.25.
Omeros Corp. (NASDAQ: OMER) is expected to release data from its Phase 2 study of OMS721/IgAN in patients not taking steroids (U.S. cohort). Shares of Omeros closed Friday at $18.14. The consensus analyst target is $36.40, and the 52-week range is $8.36 to $25.20.
Tesaro Inc. (NASDAQ: TSRO) is expected to issue an update on its regulatory discussions with FDA regarding niraparib in breast cancer. Shares of Omeros closed Friday at $44.47, with a consensus analyst target of $77.67 and a 52-week range of $38.40 to $143.45.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is expected to report Phase 2 data from all its tumor-induced osteomalacia patients. Shares of Ultragenyx closed Friday at $76.87, in a 52-week range of $41.67 to $86.10 and with a consensus analyst target of $68.74.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
